Stocks News

LAST PRICE
43.8800
TODAY'S CHANGE (%)
Trending Down-1.2300 (-2.7267%)

Bid / Lots
42.1900/ 1
Ask / Lots
45.6500/ 1
Open / Previous Close
44.7700 / 45.1100
Day Range
Low 43.1800
High 45.3750
52 Week Range
Low 21.9200
High 47.2400
Volume
428,781
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 27, 2024
- DJ PTC Therapeutics Is Maintained at Outperform by Baird, from 8:19AM ET on Wednesday Nov 27, 2024 by Dow Jones
  8:19AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: PTCT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/PTCT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 27, 2024 08:19 ET (13:19 GMT)
- PTC Therapeutics to Sell Rare Pediatric Disease Voucher for $150 Million, from 7:26AM ET on Wednesday Nov 27, 2024 by MT Newswires
  7:26AM ET on Wednesday Nov 27, 2024 by MT Newswires
  Companies Mentioned: PTCT
  07:26 AM EST, 11/27/2024 (MT Newswires) -- PTC Therapeutics (PTCT) said Wednesday it agreed to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, upon completion of the transaction. The voucher was granted on Nov. 13 along wit...
- PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million, from 7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire
  7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire
  Companies Mentioned: PTCT
  PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
- PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: PTCT
  
  PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
  
  PR Newswire
  
  WARREN, N.J., Nov. 27, 2024
  
  WARREN, N.J., Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Nov 26, 2024
- PTC Therapeutics' Amyotrophic Lateral Sclerosis Trial Fails to Meet Endpoints; Shares Fall After Hours, from 5:23PM ET on Tuesday Nov 26, 2024 by MT Newswires
  5:23PM ET on Tuesday Nov 26, 2024 by MT Newswires
  Companies Mentioned: PTCT
  05:23 PM EST, 11/26/2024 (MT Newswires) -- PTC Therapeutics (PTCT) said late Tuesday that a global phase 2 trial of Utreloxastat in patients with amyotrophic lateral sclerosis failed to meet its primary and secondary efficacy endpoints. The study di...

Yesterday
- HUTCHMED Announces Continued Inclusion of ORPATHYS(R) (savolitinib) in the National Reimbursement Drug List in China at Current Terms, from 5:30AM ET on Thursday Nov 28, 2024 by Dow Jones
  5:30AM ET on Thursday Nov 28, 2024 by Dow Jones
  Companies Mentioned: HCM
Nov 26, 2024
- Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference, from 4:05PM ET on Tuesday Nov 26, 2024 by Accesswire
  4:05PM ET on Tuesday Nov 26, 2024 by Accesswire
  Companies Mentioned: AMPH
- Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference, from 4:05PM ET on Tuesday Nov 26, 2024 by Dow Jones
  4:05PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: AMPH
- The Broken Coast Difference: Tilray Brands' Broken Coast Craft Cannabis Introduces New Premium Strain 'Platinum Pav ', from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: TLRY
Nov 23, 2024
- DJ This Cannabis Company Is Snapping Up America's Craft Beer Brewers -- WSJ, from 5:30AM ET on Saturday Nov 23, 2024 by Dow Jones
  5:30AM ET on Saturday Nov 23, 2024 by Dow Jones
  Companies Mentioned: TLRY
Nov 22, 2024
- DJ Amphastar Pharmaceuticals Initiated at Overweight by Wells Fargo, from 9:08AM ET on Friday Nov 22, 2024 by Dow Jones
  9:08AM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: AMPH
- Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan, from 4:01AM ET on Friday Nov 22, 2024 by MT Newswires
  4:01AM ET on Friday Nov 22, 2024 by MT Newswires
  Companies Mentioned: TAK, HCM
Nov 21, 2024
- HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 11:30PM ET on Thursday Nov 21, 2024 by GlobeNewswire
  11:30PM ET on Thursday Nov 21, 2024 by GlobeNewswire
  Companies Mentioned: TAK, HCM
- HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 11:30PM ET on Thursday Nov 21, 2024 by Dow Jones
  11:30PM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: TAK, HCM
- Prestige Consumer Healthcare Insider Sold Shares Worth $898,241, According to a Recent SEC Filing, from 4:08PM ET on Thursday Nov 21, 2024 by MT Newswires
  4:08PM ET on Thursday Nov 21, 2024 by MT Newswires
  Companies Mentioned: PBH

PTC Therapeutics Inc
NASDAQ:PTCTUnited States

Search Criteria

Nov 27, 2024

DJ PTC Therapeutics Is Maintained at Outperform by Baird, from 8:19AM ET on Wednesday Nov 27, 2024 by Dow Jones

PTC Therapeutics to Sell Rare Pediatric Disease Voucher for $150 Million, from 7:26AM ET on Wednesday Nov 27, 2024 by MT Newswires

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million, from 7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones

Nov 26, 2024

PTC Therapeutics' Amyotrophic Lateral Sclerosis Trial Fails to Meet Endpoints; Shares Fall After Hours, from 5:23PM ET on Tuesday Nov 26, 2024 by MT Newswires

Peers Headlines

Yesterday

HUTCHMED Announces Continued Inclusion of ORPATHYS(R) (savolitinib) in the National Reimbursement Drug List in China at Current Terms, from 5:30AM ET on Thursday Nov 28, 2024 by Dow Jones

Nov 26, 2024

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference, from 4:05PM ET on Tuesday Nov 26, 2024 by Accesswire

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference, from 4:05PM ET on Tuesday Nov 26, 2024 by Dow Jones

The Broken Coast Difference: Tilray Brands' Broken Coast Craft Cannabis Introduces New Premium Strain 'Platinum Pav ', from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 23, 2024

DJ This Cannabis Company Is Snapping Up America's Craft Beer Brewers -- WSJ, from 5:30AM ET on Saturday Nov 23, 2024 by Dow Jones

Nov 22, 2024

DJ Amphastar Pharmaceuticals Initiated at Overweight by Wells Fargo, from 9:08AM ET on Friday Nov 22, 2024 by Dow Jones

Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan, from 4:01AM ET on Friday Nov 22, 2024 by MT Newswires

Nov 21, 2024

HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 11:30PM ET on Thursday Nov 21, 2024 by GlobeNewswire

HUTCHMED Announces Launch by Takeda of FRUZAQLA(R) (fruquintinib) in Japan, from 11:30PM ET on Thursday Nov 21, 2024 by Dow Jones

Prestige Consumer Healthcare Insider Sold Shares Worth $898,241, According to a Recent SEC Filing, from 4:08PM ET on Thursday Nov 21, 2024 by MT Newswires